Atomoxetine Hydrochloride Patent Expiration
Atomoxetine Hydrochloride is Used for managing symptoms of attention-deficit hyperactivity disorder. It was first introduced by Eli Lilly And Co
Atomoxetine Hydrochloride Patents
Given below is the list of patents protecting Atomoxetine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Strattera |
US5658590 (Pediatric) | Treatment of attention-deficit/hyperactivity disorder |
May 26, 2017
(Expired) | Lilly |
| Strattera | US5658590 | Treatment of attention-deficit/hyperactivity disorder |
Nov 26, 2016
(Expired) | Lilly |
Atomoxetine Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List